Poniard Pharmaceuticals Stock Debt To Equity
| PARDDelisted Stock | USD 0.01 0.00 0.00% |
Poniard Pharmaceuticals fundamentals help investors to digest information that contributes to Poniard Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Poniard Pink Sheet. The fundamental analysis module provides a way to measure Poniard Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poniard Pharmaceuticals pink sheet.
Poniard |
Poniard Pharmaceuticals Company Debt To Equity Analysis
Poniard Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Poniard Pharmaceuticals Debt To Equity | 0.53 % |
Most of Poniard Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poniard Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Poniard Pharmaceuticals has a Debt To Equity of 0.526%. This is 99.02% lower than that of the Biotechnology sector and 97.28% lower than that of the Health Care industry. The debt to equity for all United States stocks is 98.92% higher than that of the company.
Poniard Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poniard Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Poniard Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Poniard Pharmaceuticals by comparing valuation metrics of similar companies.Poniard Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Poniard Fundamentals
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 434.76 K | ||||
| Shares Outstanding | 1.5 M | ||||
| Number Of Shares Shorted | 47.72 K | ||||
| Price To Earning | (0.01) X | ||||
| Price To Book | 0.1 X | ||||
| EBITDA | (13.04 M) | ||||
| Net Income | (30.05 M) | ||||
| Cash And Equivalents | 1.98 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.57 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 0.76 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (24.28 M) | ||||
| Short Ratio | 2.56 X | ||||
| Earnings Per Share | (3.79) X | ||||
| Target Price | 1.0 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 29 | ||||
| Total Asset | 11.64 M | ||||
| Retained Earnings | (438.94 M) | ||||
| Working Capital | 3.6 M | ||||
| Current Asset | 5.22 M | ||||
| Current Liabilities | 1.62 M | ||||
| Z Score | -55.1 | ||||
| Net Asset | 11.64 M |
About Poniard Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Poniard Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poniard Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poniard Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Poniard Pink Sheet
If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |